PE20030608A1 - Composicion y metodo para tratar diabetes - Google Patents
Composicion y metodo para tratar diabetesInfo
- Publication number
- PE20030608A1 PE20030608A1 PE2002001014A PE2002001014A PE20030608A1 PE 20030608 A1 PE20030608 A1 PE 20030608A1 PE 2002001014 A PE2002001014 A PE 2002001014A PE 2002001014 A PE2002001014 A PE 2002001014A PE 20030608 A1 PE20030608 A1 PE 20030608A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- composition
- islets
- polypeptide
- treat diabetes
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- -1 AMINO Chemical class 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 210000004153 islets of langerhan Anatomy 0.000 abstract 1
- 239000008176 lyophilized powder Substances 0.000 abstract 1
- 230000009707 neogenesis Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/474—Pancreatic thread protein; Reg protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4733—Acute pancreatitis-associated protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN POLIPEPTIDO QUE TIENE POR LO MENOS QUINCE AMINOACIDOS CONSECUTIVOS DE UNA PROTEINA ASOCIADA A LA NEOGENESIS DE ISLOTES MAMIFEROS QUE OCURRE NATURALEMENTE DONDE LA SECUENCIA DE AMINOACIDOS ES SEQ ID NO:1; SEQ ID NO:2, SEQ IDE NO:3 Y FRAGMENTOS DE ESTE, CON UN pH DE 4-6. LA COMPOSICION COMPRENDE DE 0,1 mg A 300 mg DEL POLIPEPTIDO Y ESTA EN FORMA DE POLVO LIOFILIZADO. LA FORMULACION REGENERA LOS ISLOTES DE LANGERHANS, CELULAS BETA PANCREATICAS O ESTABLECE REGULACION DE LA GLUCOSA Y ES UTIL EN EL TRATAMIENTO DE DIABETES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32933001P | 2001-10-16 | 2001-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030608A1 true PE20030608A1 (es) | 2003-08-26 |
Family
ID=23284879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002001014A PE20030608A1 (es) | 2001-10-16 | 2002-10-15 | Composicion y metodo para tratar diabetes |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20040132644A1 (es) |
| EP (1) | EP1435995A2 (es) |
| JP (1) | JP2005506362A (es) |
| KR (1) | KR20050036865A (es) |
| CN (1) | CN1723034A (es) |
| BR (1) | BR0213291A (es) |
| CA (1) | CA2463769A1 (es) |
| CO (2) | CO5570658A2 (es) |
| CZ (1) | CZ2004479A3 (es) |
| HU (1) | HUP0401612A3 (es) |
| IL (1) | IL161073A0 (es) |
| MA (1) | MA27503A1 (es) |
| MX (1) | MXPA04003526A (es) |
| NO (1) | NO20042012L (es) |
| PE (1) | PE20030608A1 (es) |
| PL (1) | PL370069A1 (es) |
| RU (1) | RU2004114865A (es) |
| SK (1) | SK1702004A3 (es) |
| WO (1) | WO2003033808A2 (es) |
| ZA (1) | ZA200402261B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060009516A1 (en) * | 2002-10-24 | 2006-01-12 | Mcgill University | Use of ingap for reversing diabetes |
| JP2008531730A (ja) * | 2005-03-04 | 2008-08-14 | キュアーディーエム、インク． | Ｉ型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物 |
| US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
| CA2726759C (en) * | 2005-05-25 | 2016-02-16 | Curedm Group Holdings, Llc | Human proislet peptide, derivatives and analogs thereof, and methods of using same |
| EP1840573A1 (en) * | 2006-03-27 | 2007-10-03 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
| US8785400B2 (en) * | 2006-11-22 | 2014-07-22 | Curedm Group Holdings, Llc | Methods and compositions relating to islet cell neogenesis |
| NZ599755A (en) * | 2007-08-30 | 2013-08-30 | Curedm Group Holdings Llc | Compositions and methods of using proislet peptides and analogs thereof |
| CA2886442A1 (en) * | 2012-09-27 | 2014-04-03 | Claresa LEVETAN | Generation of new pancreatic beta cells |
| CN104045698B (zh) * | 2013-03-15 | 2019-04-16 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
| CN104045699A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
| CN104045702A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
| US20160039877A1 (en) | 2013-03-15 | 2016-02-11 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| CN103305457B (zh) * | 2013-06-06 | 2015-07-08 | 浙江省医学科学院 | 一种体外扩增胰岛β细胞的方法 |
| US20160039876A1 (en) * | 2014-03-28 | 2016-02-11 | Claresa Levetan | Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide |
| EP3426678A4 (en) * | 2016-03-10 | 2020-03-11 | Shenzhen Hightide Biopharmaceutical, Ltd. | CONJUGATES OF ISLAND CELL NEOGENESEPEPTIDES AND ANALOGS AND METHODS THEREFOR |
| US20210196646A1 (en) * | 2018-08-15 | 2021-07-01 | Wake Forest University Health Sciences | Improved formulations for pancreatic islet encapsulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US127624A (en) * | 1872-06-04 | Improvement in apparatus for elevating water | ||
| US4658957A (en) * | 1985-01-28 | 1987-04-21 | Abbott Laboratories | Utility tray |
| US6106840A (en) * | 1988-06-23 | 2000-08-22 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
| ATE494374T1 (de) * | 1995-02-22 | 2011-01-15 | Eastern Virginia Med School | Ingap-protein und dessen beteiligung an der neogenese pankreatischer inselzellen |
| US5834590A (en) * | 1995-02-22 | 1998-11-10 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Ingap protein involved in pancreatic islet neogenesis |
| CN1152962C (zh) * | 1996-05-03 | 2004-06-09 | 艾博特公司 | 新型抗血管生成肽、其编码多核苷酸和抑制血管生成的方法 |
| US6090577A (en) * | 1997-05-22 | 2000-07-18 | Incyte Pharmaceuticals, Inc. | Disease associated acidic protein |
| US6986994B2 (en) * | 2001-01-09 | 2006-01-17 | Gmp Endotherapeutics, Inc. | INGAP displacement assays |
-
2002
- 2002-09-24 US US10/253,733 patent/US20040132644A1/en not_active Abandoned
- 2002-10-15 PE PE2002001014A patent/PE20030608A1/es not_active Application Discontinuation
- 2002-10-15 KR KR1020047005586A patent/KR20050036865A/ko not_active Ceased
- 2002-10-15 JP JP2003536523A patent/JP2005506362A/ja active Pending
- 2002-10-15 BR BR0213291-5A patent/BR0213291A/pt not_active IP Right Cessation
- 2002-10-15 IL IL16107302A patent/IL161073A0/xx unknown
- 2002-10-15 PL PL02370069A patent/PL370069A1/xx not_active Application Discontinuation
- 2002-10-15 HU HU0401612A patent/HUP0401612A3/hu unknown
- 2002-10-15 RU RU2004114865/15A patent/RU2004114865A/ru not_active Application Discontinuation
- 2002-10-15 SK SK170-2004A patent/SK1702004A3/sk not_active Application Discontinuation
- 2002-10-15 CN CNA028201922A patent/CN1723034A/zh active Pending
- 2002-10-15 EP EP02780465A patent/EP1435995A2/en not_active Ceased
- 2002-10-15 MX MXPA04003526A patent/MXPA04003526A/es unknown
- 2002-10-15 WO PCT/US2002/032904 patent/WO2003033808A2/en not_active Application Discontinuation
- 2002-10-15 CA CA002463769A patent/CA2463769A1/en not_active Abandoned
- 2002-10-15 CZ CZ2004479A patent/CZ2004479A3/cs unknown
-
2004
- 2004-03-23 ZA ZA200402261A patent/ZA200402261B/en unknown
- 2004-04-02 CO CO04031543A patent/CO5570658A2/es not_active Application Discontinuation
- 2004-04-09 MA MA27627A patent/MA27503A1/fr unknown
- 2004-05-14 NO NO20042012A patent/NO20042012L/no not_active Application Discontinuation
- 2004-06-25 CO CO04060289A patent/CO5590933A2/es not_active Application Discontinuation
-
2007
- 2007-12-04 US US11/999,208 patent/US20080171704A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2004114865A (ru) | 2005-05-27 |
| CZ2004479A3 (cs) | 2005-01-12 |
| CO5590933A2 (es) | 2005-12-30 |
| CO5570658A2 (es) | 2005-10-31 |
| US20040132644A1 (en) | 2004-07-08 |
| WO2003033808A2 (en) | 2003-04-24 |
| WO2003033808A3 (en) | 2003-09-18 |
| US20080171704A1 (en) | 2008-07-17 |
| JP2005506362A (ja) | 2005-03-03 |
| CN1723034A (zh) | 2006-01-18 |
| SK1702004A3 (sk) | 2005-03-04 |
| IL161073A0 (en) | 2004-08-31 |
| PL370069A1 (en) | 2005-05-16 |
| NO20042012L (no) | 2004-07-16 |
| EP1435995A2 (en) | 2004-07-14 |
| BR0213291A (pt) | 2004-10-26 |
| HUP0401612A2 (hu) | 2004-12-28 |
| ZA200402261B (en) | 2004-09-28 |
| MA27503A1 (fr) | 2005-09-01 |
| CA2463769A1 (en) | 2003-04-24 |
| HUP0401612A3 (en) | 2006-04-28 |
| KR20050036865A (ko) | 2005-04-20 |
| MXPA04003526A (es) | 2004-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030608A1 (es) | Composicion y metodo para tratar diabetes | |
| NO980155L (no) | Stabilisert farmasöytisk preparat som omfatter et veksthormon som er forbehandlet med sink og eventuelt lysin eller kasiumioner | |
| AR012540A1 (es) | COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN | |
| DK1654287T3 (da) | CD20-bindende polypeptidsammensætninger | |
| ES2178000T3 (es) | Composiciones y metodos para tratar infecciones usando analogos de indolicidina. | |
| PT699686E (pt) | Fragmentos de peptido insulinotropico do tipo glucagona biologicamente activos | |
| BRPI0510817A (pt) | protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença | |
| PE20120425A1 (es) | Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga | |
| ATE384743T1 (de) | Aminoterminal modifizierte parathyroidhormon (pth) analoge | |
| PE20160507A1 (es) | Diferenciacion de celulas madre mesenquimales | |
| BR9809951A (pt) | Método para tratamento da obesidade | |
| AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
| RU2013126581A (ru) | Мутанты стрептокиназы и их ковалентно модифицированные формы | |
| BR9105783A (pt) | Polipeptidio,processo para o tratamento em vidro de neuronios e composicoes celular e farmaceutica | |
| ATE322503T1 (de) | Gefrierschutzprotein | |
| ATE210149T1 (de) | Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden | |
| BRPI0616936B8 (pt) | composição farmacêutica | |
| BR0305039A (pt) | Uso de compostos que possuem a atividade biológica de peptìdeo vasoativo intestinal para o tratamento da sarcoidose | |
| PT817646E (pt) | Metodos de tratamento da inflamacao e formulacoes para esse fim | |
| ATE494301T1 (de) | Alpha-fetoprotein-peptide und ihre verwendung | |
| ATE474589T1 (de) | Angiogene peptide und ihre verwendungen | |
| ES2421407T3 (es) | Agente y composición para la curación de heridas | |
| NZ518772A (en) | Polypeptide fragments comprising c-terminal portion of helicobacter catalase | |
| DK1960515T3 (da) | Inflammationshæmmende peptider | |
| WO1998053838A3 (en) | A soluble laminin receptor precursor and methods to inhibit its interactions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |